• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $PAND

    Pandion Therapeutics Inc.

    Subscribe to $PAND
    $PAND

    IPO Year: 2020

    Exchange: NASDAQ

    Recent Analyst Ratings for Pandion Therapeutics Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    Pandion Therapeutics Inc. SEC Filings

    See more
    • SEC Form 15-12B filed by Pandion Therapeutics Inc.

      15-12B - Pandion Therapeutics, Inc. (0001807901) (Filer)

      4/12/21 6:54:59 AM ET
      $PAND
    • SEC Form EFFECT filed by Pandion Therapeutics Inc.

      EFFECT - Pandion Therapeutics, Inc. (0001807901) (Filer)

      4/6/21 12:15:17 AM ET
      $PAND
    • SEC Form EFFECT filed by Pandion Therapeutics Inc.

      EFFECT - Pandion Therapeutics, Inc. (0001807901) (Filer)

      4/6/21 12:15:16 AM ET
      $PAND
    • SEC Form S-8 POS filed by Pandion Therapeutics Inc.

      S-8 POS - Pandion Therapeutics, Inc. (0001807901) (Filer)

      4/1/21 8:49:28 AM ET
      $PAND
    • SEC Form S-8 POS filed by Pandion Therapeutics Inc.

      S-8 POS - Pandion Therapeutics, Inc. (0001807901) (Filer)

      4/1/21 8:48:58 AM ET
      $PAND
    • SEC Form POS AM filed by Pandion Therapeutics Inc.

      POS AM - Pandion Therapeutics, Inc. (0001807901) (Filer)

      4/1/21 8:47:51 AM ET
      $PAND
    • SEC Form POS AM filed by Pandion Therapeutics Inc.

      POS AM - Pandion Therapeutics, Inc. (0001807901) (Filer)

      4/1/21 8:46:51 AM ET
      $PAND
    • Pandion Therapeutics Inc. filed SEC Form 8-K: Completion Of Acquisition Or Disposition Of Assets, Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing, Material Modification To Rights Of Security Holders, Changes In Control Of Registrant, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Amendments To Articles Of Incorporation Or Bylaws; Change Of Fiscal Year, Financial Statements And Exhibits

      8-K - Pandion Therapeutics, Inc. (0001807901) (Filer)

      4/1/21 8:45:00 AM ET
      $PAND
    • SEC Form SC 14D9/A filed by Pandion Therapeutics Inc.

      SC 14D9/A - Pandion Therapeutics, Inc. (0001807901) (Subject)

      4/1/21 8:43:52 AM ET
      $PAND
    • SEC Form SC TO-T/A filed by Pandion Therapeutics Inc.

      SC TO-T/A - Pandion Therapeutics, Inc. (0001807901) (Subject)

      4/1/21 8:37:35 AM ET
      $PAND

    Pandion Therapeutics Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SVB Leerink resumed coverage on Pandion Therapeutics with a new price target

      SVB Leerink resumed coverage of Pandion Therapeutics with a rating of Market Perform and set a new price target of $60.00

      3/4/21 8:24:57 AM ET
      $PAND
    • Morgan Stanley resumed coverage on Pandion Therapeutics with a new price target

      Morgan Stanley resumed coverage of Pandion Therapeutics with a rating of Equal Weight and set a new price target of $60.00 from $25.00 previously

      3/4/21 8:24:08 AM ET
      $PAND
    • Pandion Therapeutics downgraded by Morgan Stanley with a new price target

      Morgan Stanley downgraded Pandion Therapeutics from Overweight to Equal-Weight and set a new price target of $60.00 from $25.00 previously

      2/26/21 9:18:02 AM ET
      $PAND
    • Pandion Therapeutics downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Pandion Therapeutics from Outperform to Market Perform and set a new price target of $60.00

      2/26/21 5:56:15 AM ET
      $PAND
    • Pandion Therapeutics downgraded by Morgan Stanley

      Morgan Stanley downgraded Pandion Therapeutics from Overweight to Equal Weight

      2/25/21 4:16:29 PM ET
      $PAND

    Pandion Therapeutics Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: L. Joanne Viney decreased direct ownership by 100% to 0 units

      4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)

      4/1/21 7:59:21 PM ET
      $PAND
    • SEC Form 4: Vikas Goyal decreased direct ownership by 100% to 0 units

      4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)

      4/1/21 7:58:39 PM ET
      $PAND
    • SEC Form 4: L Alan Crane decreased direct ownership by 100% to 0 units

      4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)

      4/1/21 7:57:32 PM ET
      $PAND
    • SEC Form 4: D. Edward Freedman decreased direct ownership by 100% to 0 units

      4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)

      4/1/21 7:55:34 PM ET
      $PAND
    • SEC Form 4 filed by Gregg Beloff

      4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)

      4/1/21 7:53:42 PM ET
      $PAND
    • SEC Form 4: Rahul Kakkar decreased direct ownership by 100% to 0 units

      4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)

      4/1/21 7:50:04 PM ET
      $PAND
    • SEC Form 4 filed by Christopher Fuglesang

      4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)

      4/1/21 7:49:41 PM ET
      $PAND
    • SEC Form 4: J. Daniel Becker decreased direct ownership by 100% to 0 units

      4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)

      4/1/21 7:49:34 PM ET
      $PAND
    • SEC Form 4: John Sundy decreased direct ownership by 100% to 0 units

      4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)

      4/1/21 7:46:47 PM ET
      $PAND
    • SEC Form 4: Nancy Stagliano decreased direct ownership by 100% to 0 units

      4 - Pandion Therapeutics, Inc. (0001807901) (Issuer)

      4/1/21 7:46:19 PM ET
      $PAND